Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

Biotechnology

Delix Therapeutics

Mark Rus

Milan Chytil

Kurt Rasmussen

Eliseo Salinas

Matt Gorman

Tricia Mccall

Sharon Engel

Retsina Meyer

David Olson

The Advisory team at Delix Therapeutics provides strategic guidance and expert insights to support the development and regulatory approval of non-hallucinogenic psychedelic therapies. Comprised of experienced advisors, this team collaborates closely with research, clinical, and regulatory departments to ensure that the company's innovative psychoplastogen compounds meet safety, efficacy, and compliance standards.

Advisory

Corporate Strategy

Leadership Team

Advisory

About

Team members

Other teams at Delix Therapeutics

Corporate Strategy

Leadership Team